Search results for "Congenital muscular dystrophy"

showing 5 items of 5 documents

Congenital muscular dystrophy: from muscle to brain.

2016

Congenital muscular dystrophies (CMDs) are a wide group of muscular disorders that manifest with very early onset of muscular weakness, sometime associated to severe brain involvement. The histologic pattern of muscle anomalies is typical of dystrophic lesions but quite variable depending on the different stages and on the severity of the disorder. Recent classification of CMDs have been reported most of which based on the combination of clinical, biochemical, molecular and genetic findings, but genotype/phenotype correlation are in constant progression due to more diffuse utilization of the molecular analysis. In this article, the Authors report on CMDs belonging to the group of dystroglyc…

0301 basic medicinePediatricsmedicine.medical_specialtyMuscle-eye-brain diseaseMuscular dystrophiesDiseaseReviewSeverity of Illness IndexNODiagnosis Differential03 medical and health sciencesMuscular dystrophie0302 clinical medicineBrain involvement; Congenital muscle diseases; Fukuyama congenital muscular dystrophy; Muscle-eye-brain disease; Muscular dystrophies; Walker-Warburg syndrome;Fukuyama congenital muscular dystrophySeverity of illnessmedicineHumansFukuyama congenital muscular dystrophyBrain involvement; Congenital muscle diseaseWalker–Warburg syndromeCongenital muscle diseasesWalker-Warburg syndromebusiness.industryInfant NewbornBrainmedicine.diseaseVery early onsetMolecular analysis030104 developmental biologyClinical diagnosisCongenital muscle diseaseCongenital muscular dystrophyPhysical therapybusinessBrain involvement030217 neurology & neurosurgery
researchProduct

121st ENMC International Workshop on Desmin and Protein Aggregate Myopathies. 7–9 November 2003, Naarden, The Netherlands

2004

The 121st European Neuromuscular Centre (ENMC)sponsored International Workshop on ‘DESMIN and Protein Aggregate Myopathies’, attended by 16 active participants from France, Germany, Poland, Spain, Sweden, the United Kingdom and the USA, was actually the fourth one in a row addressing the pathology of the muscle fibre intermediate filament desmin, its associated and similar diseases, all four [1–3] organized by Michel Fardeau and Hans H. Goebel. In his introduction, the chairman, Hans H. Goebel (Mainz), recorded the evolution of ‘Protein Aggregate Myopathies (PAM)’ which are marked by the accumulation of diverse proteins within muscle fibres as a morphologic hallmark in separate myopathies w…

Pathologymedicine.medical_specialtyProtein aggregationBiologymedicine.diseaseNemaline myopathyNeurologyPediatrics Perinatology and Child HealthmedicineCongenital muscular dystrophyMyotilinDesminNeurology (clinical)Muscle fibremedicine.symptomMyopathyIntermediate filamentGenetics (clinical)Neuromuscular Disorders
researchProduct

Transcriptome Analysis of Ullrich Congenital Muscular Dystrophy Fibroblasts Reveals a Disease Extracellular Matrix Signature and Key Molecular Regula…

2015

Background Collagen VI related myopathies encompass a range of phenotypes with involvement of skeletal muscle, skin and other connective tissues. They represent a severe and relatively common form of congenital disease for which there is no treatment. Collagen VI in skeletal muscle and skin is produced by fibroblasts. Aims & Methods In order to gain insight into the consequences of collagen VI mutations and identify key disease pathways we performed global gene expression analysis of dermal fibroblasts from patients with Ullrich Congenital Muscular Dystrophy with and without vitamin C treatment. The expression data were integrated using a range of systems biology tools. Results were validat…

Pathologymedicine.medical_specialtyUllrich congenital muscular dystrophyIntegrin alpha3Integrinlcsh:MedicineDown-RegulationAscorbic AcidBiologyMuscular DystrophiesExtracellular matrixLamininCollagen VImedicineCell AdhesionHumansGene Regulatory NetworksMuscular dystrophylcsh:ScienceWound HealingMultidisciplinarySclerosisGene Expression Profilinglcsh:RFibroblastsmedicine.diseaseMolecular biologyExtracellular MatrixUp-RegulationGene expression profilingMicroRNAsbiology.proteinlcsh:QWound healingResearch ArticleSignal Transduction
researchProduct

Abnormalities in alpha-dystroglycan expression in MDC1C and LGMD2I muscular dystrophies

2004

We recently identified mutations in the fukutin related protein (FKRP) gene in patients with congenital muscular dystrophy type 1C (MDC1C) and limb girdle muscular dystrophy type 2I (LGMD2I). The sarcolemma of these patients typically displays an immunocytochemical reduction of alpha-dystroglycan. In this report we extend these observations and report a clear correlation between the residual expression of alpha-dystroglycan and the phenotype. Three broad categories were identified. Patients at the severe end of the clinical spectrum (MDC1C) were compound heterozygote between a null allele and a missense mutation or carried two missense mutations and displayed a profound depletion of alpha-d…

musculoskeletal diseasesAdultPathologymedicine.medical_specialtyNonsense mutationBlotting WesternDNA Mutational AnalysisMedizinCompound heterozygosityPolymerase Chain ReactionMuscular DystrophiesPathology and Forensic MedicineFetusDystroglycanmedicineMissense mutationHumansPentosyltransferasesMuscular dystrophyChildDystroglycansMuscle SkeletalGeneticsFukutin-related proteinMembrane GlycoproteinsbiologyProteinsmedicine.diseasemusculoskeletal systemImmunohistochemistryCytoskeletal ProteinsPhenotypeMutationbiology.proteinCongenital muscular dystrophyLimb-girdle muscular dystrophyRegular Articles
researchProduct

Bortezomib Partially Improves Laminin α2 Chain–Deficient Muscular Dystrophy

2014

Congenital muscular dystrophy, caused by mutations in LAMA2 (the gene encoding laminin α2 chain), is a severe and incapacitating disease for which no therapy is yet available. We have recently demonstrated that proteasome activity is increased in laminin α2 chain-deficient muscle and that treatment with the nonpharmaceutical proteasome inhibitor MG-132 reduces muscle pathology in laminin α2 chain-deficient dy(3K)/dy(3K) mice. Here, we explore the use of the selective and therapeutic proteasome inhibitor bortezomib (currently used for treatment of relapsed multiple myeloma and mantle cell lymphoma) in dy(3K)/dy(3K) mice and in congenital muscular dystrophy type 1A muscle cells. Outcome measu…

Proteasome Endopeptidase ComplexApoptosisBiologyPathology and Forensic MedicineBortezomibmedicineAnimalsMyocyteMuscular dystrophyCells CulturedMultiple myelomaMuscle CellsMyogenesisBortezomibMusclesBody WeightMuscular Dystrophy Animalmedicine.diseaseBoronic AcidsFibrosisSurvival AnalysisMice Inbred C57BLDisease Models AnimalMicroRNAsGene Expression RegulationOrgan SpecificityPyrazinesCongenital muscular dystrophyCancer researchProteasome inhibitorMantle cell lymphomaLamininLocomotionmedicine.drugThe American Journal of Pathology
researchProduct